沙利度胺联合GP方案治疗晚期三阴性乳腺癌疗效观察

目的:探讨沙利度胺联合GP方案治疗晚期三阴性乳腺癌的临床疗效及不良反应.方法:对58例晚期三阴性乳腺癌随机分为沙利度胺联合GP方案组(联合组)和GP方案组(化疗组),比较2组的疗效、不良反应、肿瘤标志物及病人生存时间.结果:联合组有效率58.62%,高于化疗组的31.03%(P<0.05),中位生存时间37个月,长于化疗组的32个月(P<0.05);肿瘤标志物下降率65.51%,高于化疗组的37.93%(P<0.05);胃肠道反应率13.79%,低于化疗组的41.38%(P<0.05).2组骨髓抑制、便秘的发生率差异均无统计学意义(P>0.05),其余不良反应不明显.结论:沙利度胺联合GP方案治疗晚期三阴性乳腺癌疗效肯定,不良反应轻,值得临床进一步推广.

Curative effect of the GP combined with thalidomide in the treatment of advanced triple-negative breast cancer

Objective:To explore the curative effects and adverse reactions of GP combined with thalidomide in the treatment of advanced triple-negative breast cancer. Methods:A total of 58 patients with advanced triple-negative breast cancer were randomly divided into the GP combined with thalidomide group(combination group) and GP group(chemotherapy group)(29 cases each group). The curative effect,adverse reaction,tumor marker and median survival time( MST) between two groups were compared. Results:The effective rate in combination group(58. 62%) was higher than that in chemothreapy group(31. 03%) (P <0. 05). The MST in combination group(37 months) was higher than that in chemothreapy group(32 months)(P<0. 05). The decline rate of tumor markers in combination group(65. 51%) was higher than that in chemothreapy group(37. 93%)(P<0. 05). The gastrointestinal reaction rate in combination group(13.79%) was lower than that in chemothreapy group(41. 38%)(P<0. 05). The difference of the incidence rates of the bone marrow depression and constipation between two groups were not statistically significant(P>0. 05),other adverse rections were not obvious. Conclusions:GP combined with thalidomide in treating advanced triple-negative breast cancer is good curative effect and mild adverse reactions,which is worthy of promotion.